2024 DNA Molecular Biology 
Drug Discovery World
FEBRUARY 8, 2024
Dr O’Hara began by recognising the challenges associated with AAV therapeutic development, e.g., how plasmids are difficult to synthesize, amplify, and analyse with standard molecular biology protocols. Questions were fielded from the audience, which included: What analysis will be performed to evaluate host or other DNA contamination?
Drug Discovery World
JULY 23, 2024
3D genome folding DNA within the cell nucleus is more than the simple linear thread of primary sequence; it is tightly packed and folded non-randomly in a cell-type specific manner. From DDW Volume 25 – Issue 3, Summer 2024 Read the digital issue References: Maurano MT, Humbert R, Rynes E, et al. Science 2012;337(6099):1190-1195.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
LifeSciVC
AUGUST 5, 2024
But that initial quote isn’t from 2024, it is from an interview in 2021 with Mark Levin, CEO at Millennium (MIT Technology Review). In fact, it increased the requirement for experienced biologists to use the new genomic information and combine it with mechanistic biology to derive new therapeutic insights. One final parallel to 2001.
Alta Sciences
MARCH 1, 2024
Q&A With Dr. Norbert Makori and Pierre Jolicoeur: The Benefits of Combining Preclinical and Bioanalytical for Your Gene Therapy Studies pmjackson Fri, 03/01/2024 - 22:20 Recent advances in gene therapy have allowed for diseases to be approached differently.
Alta Sciences
AUGUST 21, 2024
Internships at Altasciences: Q&A With Our Summer Interns nbartlett Thu, 08/22/2024 - 04:44 Internships at Altasciences are more than just a stepping stone—they’re a gateway to real-world-experience and professional growth, giving the next generation opportunities to help shape progress in the drug development industry.
Broad Institute
MAY 14, 2024
William Studier for development of widely used protein- and RNA-production platform By Corie Lok May 14, 2024 Breadcrumb Home Merkin Prize in Biomedical Technology awarded to F. By Broad Communications May 14, 2024 F. Studier will be honored in a prize ceremony held on September 17, 2024. Photo courtesy of BNL.
Drug Discovery World
APRIL 30, 2024
This novel approach allows for the modulation of mRNA biology to either increase or decrease protein production, offering the versatility to target a wide range of mechanisms of action (MOA),” Slonim states. At the start of 2024, the first patients in a clinical trial investigating an mRNA cancer therapy were dosed.
Expert insights. Personalized for you.
147 
Let's personalize your content